Tag: Cancer Genetics and Genomics

Can chatbots help with genetic testing for cancer risk?

AI SummaryThe demand for cancer genetic testing is increasing, but there is a shortage of genetic counselors to assist patients. Researchers suggest that chatbots could potentially help with this issue by guiding patients through the genetic testing process. This innovation could make genetic testing more accessible and efficient for individuals seeking information about their cancer… Continue reading Can chatbots help with genetic testing for cancer risk?

Rectal Exam or Blood Test? 60% of U.S. Men Ages 45+ Have Misconceptions About Prostate Cancer Screening, as Rates of Late-Stage Diagnosis Increase

AI SummaryThe American Cancer Society survey of 1,200 men aged 45 and older in the U.S. found that 60% have misconceptions regarding prostate cancer screening, including confusion between a rectal exam and a blood test. This lack of awareness may contribute to rising rates of late-stage diagnoses.American Cancer Society survey of nearly 1,200 men aged… Continue reading Rectal Exam or Blood Test? 60% of U.S. Men Ages 45+ Have Misconceptions About Prostate Cancer Screening, as Rates of Late-Stage Diagnosis Increase

Emerging tumor repression of immune recognition is reversed by inhibiting DNA methylation

AI SummaryThe article discusses how tumor cells in emerging cancers alter their gene expression to evade immune control, a process known as immunoediting. The study found that this immunoevasion could be reversed by using a DNA methyltransferase inhibitor. This research sheds light on the importance of epigenetic regulation in tumor progression and immune recognition.Tumor cells… Continue reading Emerging tumor repression of immune recognition is reversed by inhibiting DNA methylation

Editors’ Picks, August 2024: ‘Colon Age’ Screening Recs, Stress From Violence, and More 

AI SummaryThis article highlights the Editors’ Picks from August 2024 for the American Association for Cancer Research (AACR). The selections include topics such as a new metric called “Colon Age” for early-onset colorectal cancer screening, the relationship between exposure to neighborhood violence and glucocorticoid receptor signaling in lung tumors, and the development of a CD33-targeting… Continue reading Editors’ Picks, August 2024: ‘Colon Age’ Screening Recs, Stress From Violence, and More 

New study supports annual breast cancer screening for women over 40

AI SummaryThis content discusses the findings of a new study that supports annual breast cancer screening for women over the age of 40. The research shows that women who had regular annual screening mammograms were less likely to have late-stage cancer and had higher overall survival rates compared to those who received screenings less frequently.… Continue reading New study supports annual breast cancer screening for women over 40

Precision drug olaparib may be effective without hormone therapy for some men with biochemically recurrent prostate cancer

AI SummaryThis article discusses a phase II clinical trial showing that the drug olaparib may be effective in treating biochemically recurrent prostate cancer in men with mutations in genes like BRCA2, without the need for hormone therapy. This suggests that olaparib could be a potentially precise treatment option for this specific group of patients.The anti-cancer… Continue reading Precision drug olaparib may be effective without hormone therapy for some men with biochemically recurrent prostate cancer

DOT1L-mediated RAP80 methylation promotes BRCA1 recruitment to elicit DNA repair

AI SummaryThis article discusses how DOT1L-mediated methylation of RAP80 promotes the recruitment of BRCA1 for DNA repair processes. This mechanism plays a crucial role in maintaining genomic stability and preventing the development of cancer. The findings offer insights into potential therapeutic targets for enhancing DNA repair mechanisms in cancer cells.

Factors associated with an inconclusive result from commercial homologous recombination deficiency testing in ovarian cancer

AI SummaryThis article discusses factors associated with obtaining an inconclusive result from commercial homologous recombination deficiency (HRD) testing in ovarian cancer. The study found that high-grade serous ovarian cancers had higher genomic instability scores (GIS) than other histologic types, with most HRD cases being of high-grade serous histology. Factors such as chemotherapy exposure and tissue… Continue reading Factors associated with an inconclusive result from commercial homologous recombination deficiency testing in ovarian cancer